| Literature DB >> 18928539 |
Olga Martínez-Augustin1, Manel Merlos, Antonio Zarzuelo, María Dolores Suárez, Fermín Sánchez de Medina.
Abstract
BACKGROUND: Trinitrobenzenesulphonic acid (TNBS) induced rat colitis is one of the most widely used models of inflammatory bowel disease (IBD), a condition whose aetiology and pathophysiology are incompletely understood. We have characterized this model at the genomic level using a longitudinal approach. Six control rats were compared with colitic animals at 2, 5, 7 and 14 days after TNBS administration (n = 3). The Affymetrix Rat Expression Array 230 2.0 system was used.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18928539 PMCID: PMC2577662 DOI: 10.1186/1471-2164-9-490
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Inflammatory biochemical and morphological markers in TNBS-induced colitis. All means were different from the control values, except for body weight gain at 14 days (not shown).
Figure 2Time course changes of gene expression in rat TNBS colitis. Sample clustering by two-way analysis of variance. Upregulated genes are shown in red and downregulated genes in green. The difference between TNBS colitis and control samples was greatest on day 7.
Figure 3Postgenomic validation of microarray data. Correspondence between mean fold change (FC) values obtained by microarray (X) and qRT-PCR (Y) analysis. The diagonal line represents the ideal correspondence trend.
Gene ontology categories most affected by TNBS colitis at different time points
| Gene ontology category | z value | ||
| Day 2 | Biological process | Positive regulation of anti-apoptosis | 5.033 |
| Leukocyte chemotaxis | 5.199 | ||
| Cellular component | Phosphoinositide 3-kinase complex | 4.202 | |
| Molecular function | Chemokine activity | 5.721 | |
| 1-Phosphatidylinositol 3-kinase activity | 4.582 | ||
| Unfolded protein binding | 4.022 | ||
| Day 5 | Biological process | Immune system process | 6.507 |
| Immune response | 6.088 | ||
| Defence response | 6.025 | ||
| Response to external stimulus | 5.402 | ||
| Antigen processing and presentation of peptide antigen | 5.128 | ||
| Lymphocyte mediated immunity | 4.962 | ||
| Cell death | 4.910 | ||
| Response to other organism | 4.532 | ||
| Leukocyte migration | 4.506 | ||
| Cytokine biosynthetic process | 4.484 | ||
| Phagocytosis, recognition | 4.473 | ||
| Positive regulation of lymphocyte differentiation | 4.348 | ||
| Vasculature development | 4.320 | ||
| Protein amino acid dephosphorylation | 4.289 | ||
| Regulation of inflammatory response | 4.190 | ||
| T cell differentiation | 4.091 | ||
| Peptide antigen transport | 4.044 | ||
| Regulation of protein binding | 4.001 | ||
| Organelle fusion | 4.001 | ||
| Cellular component | MHC class II protein complex | 4.900 | |
| Mitochondrial respiratory chain | 4.384 | ||
| TAP complex | 4.374 | ||
| Molecular function | Haematopoietin/interferon-class (D200-domain) cytokine receptor activity | 5.107 | |
| Protein tyrosine phosphatase activity | 4.871 | ||
| Cytokine activity | 4.600 | ||
| Chemokine activity | 4.277 | ||
| NADH dehydrogenase activity | 4.133 | ||
| Peptide antigen-transporting ATPase activity | 4.044 | ||
| Phosphatidylserine binding | 4.001 | ||
| Day 7 | Biological process | Leukocyte chemotaxis | 4.936 |
| Immune system process | 4.332 | ||
| Response to external stimulus | 4.323 | ||
| Antigen processing and presentation of exogenous peptide antigen | 4.124 | ||
| Cellular component | Extracellular matrix part | 5.849 | |
| Proteinaceus extracellular matrix | 4.931 | ||
| Collagen | 4.674 | ||
| Basement membrane | 4.280 | ||
| Actin filament | 4.115 | ||
| Molecular function | Extracellular matrix constituent | 4.710 | |
| Day 14 | Biological process | Defence response | 5.420 |
| Prophyrin catabolic process | 5.286 | ||
| Immune response | 5.082 | ||
| Lymphocyte homeostasis | 5.029 | ||
| DNA damage response, signal transduction by p53 class mediator | 4.414 | ||
| Glial cell migration | 4.414 | ||
| Leukocyte activation | 4.366 | ||
| Inflammatory response | 4.362 | ||
| RNA destabilization | 4.316 | ||
| Positive regulation of interferon-gamma production | 4.316 | ||
| Heme oxidation | 4.316 | ||
| Vasodilation | 4.231 | ||
| Cytokine biosynthetic process | 4.142 | ||
| Cellular component | External side of plasma membrane | 5.339 | |
| Costamere | 4.316 | ||
| B cell receptor complex | 4.316 | ||
| Molecular function | Double-stranded DNA adenosine deaminase activity | 5.286 | |
| Interleukin 1, Type I receptor binding | 4.316 | ||
| DNA ligase (ATP) activity | 4.316 | ||
| Heme oxygenase (decyclizing) activity | 4.316 | ||
| Saccharopine dehydrogenase (NAD+, L-glutamate-forming) activity | 4.316 | ||
| Thyroid hormone receptor activity | 4.316 | ||
| Cannabinoid receptor activity | 4.316 | ||
Non-redundant categories with z values > 4 are shown. A high z value indicates a higher representation of significantly changed genes than expected.
Genes modulated specifically at day 2
| Gene symbol | Gene name | FC | SEM |
| Hla-dmb | Major histocompatibility complex, class II, DM beta | 9.13 | 0.47 |
| Fbxl7_predicted | F-box and leucine-rich repeat protein 7 (predicted) | 8.46 | 3.35 |
| Acot12 | Acyl-CoA thioesterase 12 | 8.19 | 3.28 |
| Prl8a2 | Prolactin family 8, subfamily a, member 2 | 7.86 | 2.22 |
| Tmod1 | Tropomodulin 1 | 6.66 | 0.79 |
| Sds | Serine dehydratase | 4.57 | 0.71 |
| Adcyap1r1 | Adenylate cyclase activating polypeptide 1 receptor 1 | 4.56 | 0.54 |
| Sp2 | Sp2 transcription factor | 4.05 | 0.56 |
| Vmd2l1_predicted | Vitelliform macular dystrophy 2-like protein 1 (predicted) | 2.80 | 0.32 |
| Crh | Corticotropin releasing hormone | 2.65 | 0.26 |
| Fzd4 | Frizzled homolog 4 (Drosophila) | 2.64 | 0.14 |
| Igfbp5 | Insulin-like growth factor binding protein 5 | 2.44 | 0.30 |
| CPG2 | CPG2 protein | 2.32 | 0.08 |
| Lss | Lanosterol synthase | 2.27 | 0.08 |
| Reln | Reelin | 2.10 | 0.17 |
| Atcay_predicted | Ataxia, cerebellar, Cayman type (caytaxin) (predicted) | 2.05 | 0.06 |
| Pik3c2g | Phosphatidylinositol 3-kinase, C2 domain containing, gamma polypeptide | 2.02 | 0.25 |
| Fmo2 | Flavin containing monooxygenase 2 | 1.97 | 0.22 |
| Slc13a5 | Solute carrier family 13 (sodium-dependent citrate transporter), member 5 | 1.90 | 0.11 |
| Xlkd1_predicted | Extra cellular link domain-containing 1 (predicted) | 1.81 | 0.15 |
| Vps4a | Vacuolar protein sorting 4a (yeast) | 1.64 | 0.03 |
| C1qbp | Complement component 1, q subcomponent binding protein | 1.53 | 0.10 |
| Exosc2_predicted | Exosome component 2 (predicted) | 1.52 | 0.10 |
| Map3k6_predicted | Mitogen-activated protein kinase kinase kinase 6 (predicted) | 1.51 | 0.09 |
| Retnla | Resistin like alpha | 0.05 | 0.03 |
| Csrp2 | Cysteine and glycine-rich protein 2 | 0.10 | 0.03 |
| Dmrta1_predicted | Doublesex and mab-3 related transcription factor like family A1 (predicted) | 0.11 | 0.00 |
| Rax | Retina and anterior neural fold homeobox | 0.13 | 0.04 |
| Ide | Insulin degrading enzyme | 0.14 | 0.02 |
| Opcml | Opioid-binding protein/cell adhesion molecule-like | 0.17 | 0.01 |
| Wdr22_predicted | WD repeat domain 22 (predicted) | 0.18 | 0.05 |
| Nova1 | Neuro-oncological ventral antigen 1 | 0.19 | 0.02 |
| Fgf20 | Fibroblast growth factor 20 | 0.21 | 0.01 |
| Adh6 | Alcohol dehydrogenase 6 (class V) | 0.22 | 0.02 |
| Cpg1 | Candidate plasticity gene 1 | 0.22 | 0.04 |
| Pfkfb2 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | 0.27 | 0.10 |
| Gpha2 | Glycoprotein hormone alpha 2 | 0.31 | 0.01 |
| Myt1l | Myelin transcription factor 1-like | 0.31 | 0.06 |
| Npffr2 | Neuropeptide FF receptor 2 | 0.33 | 0.07 |
| Csn2 | Casein beta | 0.34 | 0.06 |
| Sybl1 | Synaptobrevin-like 1 | 0.34 | 0.04 |
| Efcbp2 | Neuronal calcium binding 2 | 0.40 | 0.06 |
| Cbr3_predicted | Carbonyl reductase 3 (predicted) | 0.41 | 0.03 |
| Alpi | Alkaline phosphatase 1, intestinal, defined by SSR | 0.41 | 0.04 |
| Nrxn1 | Neurexin 1 | 0.43 | 0.06 |
| Gp2 | Glycoprotein 2 (zymogen granule membrane) | 0.46 | 0.03 |
| Cd248_predicted | CD248 antigen, endosialin (predicted) | 0.46 | 0.05 |
| Ppfia3 | Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3 | 0.59 | 0.02 |
| Zfp580_predicted | Zinc finger protein 580 (predicted) | 0.62 | 0.05 |
| Pttg1ip | Pituitary tumour-transforming 1 interacting protein | 0.65 | 0.05 |
Only annotated genes with a 50% or higher fold change are included. In all cases the FC at days 5–14 was not significantly different from the control (significance at P > 0.10 to exclude transcripts not specifically upregulated or downregulated at only day 2).
Genes modulated specifically at day 14
| Gene symbol | Gene name | FC | SEM |
| Tbx15_predicted | T-box 15 (predicted) | 8.00 | 1.74 |
| Trhr | Thyrotropin releasing hormone receptor | 5.67 | 1.26 |
| Ppp3cc | Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma) | 5.07 | 3.34 |
| Eif2ak3 | Eukaryotic translation initiation factor 2 alpha kinase 3 | 4.92 | 2.25 |
| Hrh3 | Histamine receptor H3 | 4.35 | 1.34 |
| Klf15 | Kruppel-like factor 15 | 3.58 | 0.39 |
| Gldc_predicted | Glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P) (predicted) | 3.40 | 1.49 |
| Trdn | Triadin | 3.18 | 0.53 |
| Galr1 | Galanin receptor 1 | 3.15 | 0.04 |
| Mlana_predicted | Melan-A (predicted) | 2.30 | 0.47 |
| Cma1 | Chymase 1, mast cell | 2.15 | 0.30 |
| Trerf1_predicted | Transcriptional regulating factor 1 (predicted) | 1.91 | 0.10 |
| Serbp1 | Serpine1 mRNA binding protein 1 | 1.85 | 0.22 |
| Ltb4dh | Leukotriene B4 12-hydroxydehydrogenase | 1.78 | 0.24 |
| Fgf1 | Fibroblast growth factor 1 | 1.75 | 0.28 |
| Ace | Angiotensin 1 converting enzyme | 1.72 | 0.33 |
| Eif4a1 | Eukaryotic translation initiation factor 4A1 | 1.68 | 0.38 |
| Adar | Adenosine deaminase, RNA-specific | 1.59 | 0.12 |
| Ddb1 | Damage-specific DNA binding protein 1 | 1.57 | 0.05 |
| Mbnl | Muscleblind-like 1 (Drosophila) | 1.52 | 0.10 |
| Lzts1 | Leucine zipper, putative tumour suppressor 1 | 1.52 | 0.16 |
| Hmga1 | High mobility group AT-hook 1 | 1.51 | 0.13 |
| Apoa5 | Apolipoprotein A-V | 0.08 | 0.01 |
| Strn | Striatin, calmodulin binding protein | 0.09 | 0.05 |
| Olfm3 | Olfactomedin 3 | 0.09 | 0.01 |
| Cdc2l5 | Cell division cycle 2-like 5 (cholinesterase-related cell division controller) | 0.11 | 0.03 |
| Prom2 | Prominin 2 | 0.11 | 0.02 |
| Snag1_predicted | Sorting nexin associated golgi protein 1 (predicted) | 0.11 | 0.03 |
| Serpina3m | Serine (or cysteine) proteinase inhibitor, clade A, member 3M | 0.12 | 0.02 |
| Ank1_predicted | Ankyrin 1, erythroid (predicted) | 0.13 | 0.00 |
| Hist1h1t | Histone 1, h1t | 0.15 | 0.02 |
| Imp1 | Insulin-like growth factor 2, binding protein 1 | 0.15 | 0.03 |
| Cacng7 | Calcium channel, voltage-dependent, gamma subunit 7 | 0.16 | 0.05 |
| Rbm9_predicted | RNA binding motif protein 9 (predicted) | 0.19 | 0.03 |
| Drp2 | Dystrophin-related protein 2 A-form splice variant | 0.20 | 0.03 |
| Eif4g1 | Eukaryotic translation initiation factor 4 gamma, 1 | 0.20 | 0.01 |
| Apob | Apolipoprotein B | 0.21 | 0.07 |
| Wt1 | Wilms tumor 1 | 0.23 | 0.02 |
| Pqlc2_predicted | PQ loop repeat containing 2 (predicted) | 0.25 | 0.07 |
| Cnr1 | Cannabinoid receptor 1 (brain) | 0.25 | 0.02 |
| Lmo3 | LIM domain only 3 | 0.26 | 0.03 |
| Bai3_predicted | Brain-specific angiogenesis inhibitor 3 (predicted) | 0.28 | 0.04 |
| Sp3 | Sp3 transcription factor | 0.31 | 0.02 |
| Apba1 | Amyloid beta (A4) precursor protein-binding, family A, member 1 | 0.32 | 0.03 |
| Kcnc3 | Potassium voltage gated channel, Shaw-related subfamily, member 3 | 0.44 | 0.06 |
| Actc1 | Actin alpha cardiac 1 | 0.45 | 0.06 |
| Wnt11 | Wingless-type MMTV integration site family, member 11 | 0.47 | 0.09 |
| Il2 | Interleukin 2 | 0.50 | 0.08 |
| Galnt2_predicted | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (predicted) | 0.57 | 0.02 |
| Nrg2 | Neuregulin 2 | 0.60 | 0.04 |
| Cspg4 | Chondroitin sulphate proteoglycan 4 | 0.60 | 0.02 |
| Enth | Enthoprotin | 0.61 | 0.03 |
| Zfp503_predicted | Zinc finger protein 503 (predicted) | 0.66 | 0.02 |
| Rbm3 | RNA binding motif (RNP1, RRM) protein 3 | 0.66 | 0.02 |
| Mpp5_predicted | Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) (predicted) | 0.66 | 0.01 |
| Prg1 | Plasticity related gene 1 | 0.67 | 0.02 |
| Csnk1d | Casein kinase 1, delta | 0.67 | 0.06 |
Only annotated genes with a 50% or higher fold change are included. In all cases the FC at days 2 – 7 was not significantly different from the control (significance at P > 0.10 to exclude transcripts that were not specifically upregulated or downregulated at only day 14).
Figure 4Behaviour over time of genes involved in inflammation and immune response. Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at p < 0.05 after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.
Figure 5Postgenomic validation of selected inflammation genes by qRT-PCR. *P < 0.05 vs. control.
Figure 6Behaviour over time of genes involved in metabolism. Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at p < 0.05 after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.
Figure 7Postgenomic validation of selected metabolic genes by qRT-PCR. *P < 0.05 vs. control.
Figure 8Behaviour over time of genes involved in cell signalling. Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at p < 0.05 after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.
Figure 9Behaviour over time of genes involved in transport. Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at p < 0.05 after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.
Figure 10Postgenomic validation of selected ion transport genes by qRT-PCR. *P < 0.05 vs. control.
Figure 11Behaviour over time of genes involved in tissue remodelling. Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at p < 0.05 after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.
Figure 12Postgenomic validation of selected tissue remodeling genes by qRT-PCR. *P < 0.05 vs. control.